AIM ImmunoTech Inc is trading 85.4% down at $0.40 after announcing a $2.65 million at-market financing on June 9, 2026.
- The financing was priced at $0.5189 per share, a move that often pressures stock prices as investors react to potential share dilution.
- While broader market conditions are currently weak, the significant decline appears to be primarily driven by this company-specific capital raise.